Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Express Scripts
McKesson
Harvard Business School
McKinsey

Last Updated: May 27, 2022

Investigational Drug Information for IW-1701


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for IW-1701?

IW-1701 is an investigational drug.

There have been 6 clinical trials for IW-1701. The most recent clinical trial was a Phase 2 trial, which was initiated on December 22nd 2017.

The most common disease conditions in clinical trials are Anemia, Sickle Cell, Esophageal Achalasia, and [disabled in preview]. The leading clinical trial sponsors are Cyclerion Therapeutics, Ironwood Pharmaceuticals, Inc., and [disabled in preview].

There are four US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for IW-1701
TitleSponsorPhase
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy VolunteersCyclerion TherapeuticsPhase 1
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy VolunteersIronwood Pharmaceuticals, Inc.Phase 1
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male VolunteersCyclerion TherapeuticsPhase 1

See all IW-1701 clinical trials

Clinical Trial Summary for IW-1701

Top disease conditions for IW-1701
Top clinical trial sponsors for IW-1701

See all IW-1701 clinical trials

US Patents for IW-1701

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IW-1701 See Plans and Pricing sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
IW-1701 See Plans and Pricing sGC stimulators Cyclerion Therapeutics, Inc. (Cambridge, MA) See Plans and Pricing
IW-1701 See Plans and Pricing sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA) See Plans and Pricing
IW-1701 See Plans and Pricing sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IW-1701

Drugname Country Document Number Estimated Expiration Related US Patent
IW-1701 Australia AU2014227862 2033-03-15 See Plans and Pricing
IW-1701 Australia AU2019203606 2033-03-15 See Plans and Pricing
IW-1701 Australia AU2021204292 2033-03-15 See Plans and Pricing
IW-1701 Brazil BR112015023349 2033-03-15 See Plans and Pricing
IW-1701 Canada CA2907111 2033-03-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Express Scripts
McKesson
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.